Clinical Trial

Neoadjuvant Folfirinox Combined With Pembrolizumab Followed by Surgery for Patients With Resectable Pancreatic Cancer

Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
Abbreviated Title: Neoadjuvant FOLFIRINOX combined with Pembrolizumab followed by surgery for patients with resectable pancreatic cancer Trial Phase: Phase II Clinical Indication: Pancreatic ductal adenocarcinoma; Adenocarcinoma; AJCC I, II, or III; 1st Line neoadjuvant Trial Type: Interventional prospective Type of control: Historical Route of administration: IV Treatment Groups: Neoadjuvant FOLFIRINOX combined with Pembrolizumab followed by surgery for patients with resectable pancreatic cancer Number of trial participants: 30 Estimated enrollment period: 24 months Estimated duration of trial: 3.5 Years Duration of Participation:16 months Estimated average length of treatment per patient: 16 months
Protocol Amendment History 10 amendments
This ClinicalTrials.gov record has been amended 10 times since 2021-11-19; most recent amendment 2025-07-17.
Status change: Not Yet Recruiting → Recruiting 2022-09-01
Trial Details
NCT Number NCT05132504
Lead Sponsor Baylor College of Medicine
Collaborators: Merck Sharp & Dohme LLC, The Methodist Hospital Research Institute
Conditions Pancreatic Ductal Adenocarcinoma
Enrollment 30 participants
Start Date 2022-08-31
Primary Completion 2027-05-21 (estimated)
Study Completion 2027-05-21 (estimated)
Updated on ClinicalTrials.gov 2026-08-04